Correction: Inify Laboratories - mandatory notification of trade
Stockholm, Sweden, 30 January 2026, Reference is made to the stock exchange announcement made by Inify Laboratories AB (publ.) (the "Company") on 27 January 2026 regarding allocation of new shares to primary insiders in the repair issue announced by the Company on 9 December 2025 (the "Repair Issue").
The number of shares allocated to board member Martin Ingvar was incorrectly stated as 67,132 in the announcement of 27 January 2026. The correct number of shares allocated to Ingvar in the Repair Issue is 67,372. Consequently, Ingvar will, subject to the completion of the Repair Issue, own 283,435 shares in the Company. A corrected notification form for Ingvar is attached hereto.
For further information, please contact CEO, Fredrik Palm, [email protected], or visit https://www.inify.com.
This information is subject to the disclosure requirements in the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act.
###
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Stockholm, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo under the ticker INIFY.